101 related articles for article (PubMed ID: 35576703)
1. Design, synthesis and biological evaluation of new parbendazole derivatives for the treatment of HNSCC.
Liang D; Yu C; Ma Z; Hu M; Wang J; Dong X; Du L; Li M
Eur J Med Chem; 2022 Aug; 238():114450. PubMed ID: 35576703
[TBL] [Abstract][Full Text] [Related]
2. Identification of anthelmintic parbendazole as a therapeutic molecule for HNSCC through connectivity map-based drug repositioning.
Liang D; Yu C; Ma Z; Yang X; Li Z; Dong X; Qin X; Du L; Li M
Acta Pharm Sin B; 2022 May; 12(5):2429-2442. PubMed ID: 35646536
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition.
Ban MJ; Byeon HK; Yang YJ; An S; Kim JW; Kim JH; Kim DH; Yang J; Kee H; Koh YW
Cancer Sci; 2018 Dec; 109(12):3816-3825. PubMed ID: 30343534
[TBL] [Abstract][Full Text] [Related]
4. Azacitidine, as a DNMT Inhibitor Decreases hTERT Gene Expression and Telomerase Activity More Effective Compared with HDAC Inhibitor in Human Head and Neck Squamous Cell Carcinoma Cell Lines.
Atri S; Nasoohi N; Hodjat M
Curr Mol Pharmacol; 2021; 14(1):60-67. PubMed ID: 32394848
[TBL] [Abstract][Full Text] [Related]
5. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
[TBL] [Abstract][Full Text] [Related]
6. Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma.
Alam MM; Marin Fermin J; Spiller PT; Burnett C; Rong X; Moore-Medlin T; Maxwell CO; Khandelwal AR; Nathan CO
Mol Carcinog; 2022 Jan; 61(1):33-44. PubMed ID: 34598317
[TBL] [Abstract][Full Text] [Related]
7. HDAC inhibitors suppress the proliferation, migration and invasiveness of human head and neck squamous cell carcinoma cells via p63‑mediated tight junction molecules and p21‑mediated growth arrest.
Kakiuchi A; Kakuki T; Ohwada K; Kurose M; Kondoh A; Obata K; Nomura K; Miyata R; Kaneko Y; Konno T; Kohno T; Himi T; Takano KI; Kojima T
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649777
[TBL] [Abstract][Full Text] [Related]
8. 5-aza-2'-deoxycytidine induces apoptosis and inhibits tumour growth in vivo of FaDu cells, a specific HPVnegative HNSCC cell line.
Miari R; Azzam N; Bar-Shalom R; Fares F
PLoS One; 2021; 16(9):e0253756. PubMed ID: 34534222
[TBL] [Abstract][Full Text] [Related]
9. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
10. CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma.
Lai YJ; Yu WN; Kuo SC; Ho CT; Hung CM; Way TD; Chen CT
J Cell Physiol; 2019 Jun; 234(6):9118-9129. PubMed ID: 30341909
[TBL] [Abstract][Full Text] [Related]
11. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
12. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
[No Abstract] [Full Text] [Related]
13. Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer.
Saleh AD; Cheng H; Martin SE; Si H; Ormanoglu P; Carlson S; Clavijo PE; Yang X; Das R; Cornelius S; Couper J; Chepeha D; Danilova L; Harris TM; Prystowsky MB; Childs GJ; Smith RV; Robertson AG; Jones SJM; Cherniack AD; Kim SS; Rait A; Pirollo KF; Chang EH; Chen Z; Van Waes C
Clin Cancer Res; 2019 May; 25(9):2860-2873. PubMed ID: 30723145
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma.
Go YY; Kim SR; Kim DY; Chae SW; Song JJ
Sci Rep; 2020 Nov; 10(1):20622. PubMed ID: 33244087
[TBL] [Abstract][Full Text] [Related]
15. Decursin inhibits tumor progression in head and neck squamous cell carcinoma by downregulating CXCR7 expression
Joo M; Heo JB; Kim S; Kim N; Jeon HJ; An Y; Song GY; Kim JM; Lee HJ
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34958113
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia-Related Head and Neck Cancer.
Montanuy H; Martínez-Barriocanal Á; Antonio Casado J; Rovirosa L; Ramírez MJ; Nieto R; Carrascoso-Rubio C; Riera P; González A; Lerma E; Lasa A; Carreras-Puigvert J; Helleday T; Bueren JA; Arango D; Minguillón J; Surrallés J
Clin Cancer Res; 2020 Jun; 26(12):3044-3057. PubMed ID: 32005748
[TBL] [Abstract][Full Text] [Related]
17. Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.
Liao J; Yang Z; Carter-Cooper B; Chang ET; Choi EY; Kallakury B; Liu X; Lapidus RG; Cullen KJ; Dan H
Clin Exp Metastasis; 2020 Apr; 37(2):283-292. PubMed ID: 32020377
[TBL] [Abstract][Full Text] [Related]
18. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
[TBL] [Abstract][Full Text] [Related]
19. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.
Yang Z; Liao J; Lapidus RG; Fan X; Mehra R; Cullen KJ; Dan H
Cancer Chemother Pharmacol; 2022 Apr; 89(4):469-478. PubMed ID: 35212780
[TBL] [Abstract][Full Text] [Related]
20. UCHL1 promotes proliferation and metastasis in head and neck squamous cell carcinoma and could be a potential therapeutic target.
Zhang D; Fu Y; Tian G; Li J; Shang D; Zhou S
Oral Surg Oral Med Oral Pathol Oral Radiol; 2022 Jun; 133(6):684-697. PubMed ID: 35165060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
